Technical Study Routine +

Voyageur Pharmaceuticals Engages Fluor to Advance Feasibility Studies for Iodine Production and Integrated Contrast Drug Manufacturing Facility

Voyageur Pharmaceuticals is advancing its North American supply chain for early-stage radiology drug development.

By The Northwire Desk — AI Analysis Jun 23, 2026 · 16:00 VM · 0.105 Voyageur Pharmaceuticals Ltd.

Executive Summary

Voyageur Pharmaceuticals has engaged Fluor Corporation to conduct comprehensive feasibility studies for two strategic projects aimed at establishing a vertically integrated North American supply chain for radiology contrast drugs.
The company has allocated US$2.35 million for the feasibility study of an iodine extraction facility in Oklahoma, developed in collaboration with Bayer AG.
A separate feasibility study for a planned integrated barium/iodine manufacturing facility will have its budget finalized after proprietary process testing.
Studies are targeted for completion in early 2027, potentially leading to a construction decision and a subsequent phase involving offtake-linked production financing from Bayer.
The initiative builds upon Health Canada-approved barium contrast products already generating commercial sales in Canada.

Material Impact

The engagement of Fluor is a logical, expected progression following the February 2026 collaboration with Bayer and the March 2026 iodine program launch.
It de-risks the technical and economic viability of the proposed North American supply chain but does not immediately alter the company's financial position or near-term cash flow.
The news is incremental to the previously announced $2.35 million Bayer funding and the $5 million private placement closed in June 2026.
No material change to the company's going concern status or immediate capital requirements is disclosed.

VM · Price

Company Overview

Voyageur Pharmaceuticals is a Canadian junior company focused on developing a vertically integrated North American supply chain for radiology contrast drugs.
Flagship Project 1: Frances Creek Barite Project (British Columbia). Contains an indicated resource of 214,800 tonnes at 35.2% BaSO4. A 2022 PEA projects a $464M pre-tax NPV and 168% IRR. The company has submitted a MYAB permit for bulk sampling and is advancing process validation for pharmaceutical-grade barium.
Flagship Project 2: Bayer Iodine Project (Oklahoma). Leverages the proprietary Mueller Process for iodine extraction from oil-field brine. Aims to produce 35 million doses/year of iodine contrast drug.
Commercial Status: Health Canada-approved barium contrast products are generating early commercial sales in Canada. FDA 505(b)(2) submissions for barium commenced in February 2026.

More from Voyageur Pharmaceuticals Ltd.